What is CRS?
- • Carrier risk screening is crucial to understand the health of your future family.1
- • Generally carried out while planning a baby, it involves identifying whether you possess a gene associated with specific genetic disorders.1
While preparing for a new addition to your family, have you considered your responsibility to your future child before conception? Exploring your genetic background can reveal potential hereditary risks your child might face. Explore the Genomic Health Insights Program by Strand Life Sciences, India's leaders in Next Generation Sequencing, and stay better informed for a brighter future and a happier family.
About Carrier Risks
How common is the occurrence?
- • More than 72 million are affected with rare diseases in India.2
- • ~1 in 3 people are carriers of one or more genetic disorders.3,*
Importance of identifying a carrier risk
Benefits:4-6- • Know the risks of passing on genetic disorders beforehand.
- • Know proactive management and prevention strategies.
The Genomic Health Insights Program
Strand Life Science's Genomic Health Insights Program (GHI) combines advanced genetic tests to identify potential hereditary risk factors. Using Next Generation Sequencing and proprietary Bioinformatics tools, GHI sequences over 20,000 genes, providing insights for enhanced wellness management.
The Genomic Health Insights Program
Strand Life Science's Genomic Health Insights Program (GHI) combines advanced genetic tests to identify potential hereditary risk factors. Using Next Generation Sequencing and proprietary Bioinformatics tools, GHI sequences over 20,000 genes, providing insights for enhanced wellness management.
Benefits of the Genomic Health Insights Program
Hereditary Cancer Risk Report
- • Predicts the risk of inherited cancers
- • Estimates the risk in family members
- • Facilitates surveillance measures by a clinician for early disease detection
Hereditary Cardiovascular Disease Report
- • Evaluates the risk of developing adult and late-onset inherited cardiovascular disease
- • Evaluates the risk in family members
- • Facilitates surveillance measures by a clinician for early disease detection
Hereditary Metabolic Disorders Report
- • Predicts the risk of developing adult and late-onset IEM diseases
- • Helps with risk estimation in family members
Carrier Risk Report
- • Identifies recessive disorders in adults that can pose a risk to their offspring
- • Forms the basis for reproductive counseling, which can reduce disease risk
Pharmacogenomics Assessment Report
- • Catalogues drugs in various categories to guide prescriptions from clinicians
- • Provides information tailored to you on toxicity and benefit of drugs
How is Strand Genomic Health Insights Program different?
Strand Genomic Health Insights (GHI) is the only program in India that uses state-of-the-art Next Generation Sequencing (NGS) technology instead of traditional Microarray technology.
Strand Life Sciences provides these advanced genetic tests using the latest genomics technology to bring these insights to you.
23-year legacy
Deep scientific expertise
Cutting-edge technology
Founded by experts from the
Indian Institute of Science.
First CAP and NABL accredited state-of-the-art genomic testing lab in the country.
Genetic Assessment
Who should get tested?
- • All healthy adults invested in an informed genomic journey of self-discovery and embracing next generation technology as a gateway to modern and preventative healthcare.
- • Those planning to start a family; testing both spouses for "Carrier Risk" will ensure a responsible approach to planning a child.
- • Those with a family history of disease to understand the probability of inheriting adult-onset disorders and guide their wellness journey.
- • All individuals who want to understand their response to commonly used drugs to help guide their clinicians while prescribing the medicines.
How to get tested?
What makes you, you?
Watch the video to know the answer!
Lisa recommends Strand Life Sciences.
Watch the video and know why she trusts Strand Life Sciences.
Patient stories
*Current estimates are from a randomly selected cohort of 80 individuals from internal Pilot Studies and are accurate up to the date of publication of these studies on this site. These nos. can change as the size of the study cohort continues to grow.
References:
1. American College of Obstetricians and Gynecologists. FAQ. Carrier Screening. [Cited on 23 August 2023]. Available at: https://www.acog.org/womens-health/faqs/carrier-screening
2. Rare disease India. [Cited on Sep 12 2023]. Available at: http://www.rarediseasesindia.org/
3. Data on file.
4. Andermann A, Blancquaert I. Genetic screening: A primer for primary care. Canadian Family Physician. 2010;56(4):333-9.
5. Nazareth SB, Lazarin GA, Goldberg JD. Changing trends in carrier screening for genetic disease in the United States. Prenatal diagnosis. 2015;35(10):931-5.
6. American College of Obstetricians and Gynecologists. Carrier Screening for Genetic Conditions. [Cited on 17 October 2023]. Available at: https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2017/03/carrier-screening-for-genetic-conditions